SMMTSummit Therapeutics Inc.

Nasdaq summittxinc.com


$ 2.38 $ -0.99 (-29.29 %)    

Tuesday, 28-May-2024 15:59:55 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 2.39
$ 3.31
$ 0.00 x 0
$ 0.00 x 0
$ 2.11 - $ 3.32
$ 1.50 - $ 5.39
13,510,795
na
1.68B
$ -0.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-initiates-coverage-on-summit-therapeutics-with-buy-rating-announces-price-target-of-7

Citigroup analyst Yigal Nochomovitz initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces ...

 summit-therapeutics-q1-eps-006-up-from-143-yoy-exits-q1-with-cash--equivalents-worth-157m

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.06) per share. This is a 95.8 percent increase over losses o...

 summit-therapeutics-ankur-dhingra-resigned-as-chief-financial-officer-of-company-appointed-its-chief-operating-officer-manmeet-soni-to-office-of-chief-financial-officer

- SEC Filing

 why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

 akeso-marks-profit-milestone-with-swift-rights-issue

Key Takeaways: Akeso swung to an annual profit of 1.94 billion yuan, boosted by licensing income of 2.92 billion yuan The n...

 analysts-eye-summit-therapeutics-ivonescimab-as-potential-challenger-to-mercks-keytruda-in-lung-cancer-treatment

Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expan...

 tesla-krispy-kreme-mccormick-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.

 stifel-initiates-coverage-on-summit-therapeutics-with-buy-rating-announces-price-target-of-8

Stifel analyst Brad Canino initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces Price Tar...

 summit-therapeutics-announced-data-for-ivonescimab-in-advanced-non-small-cell-lung-cancer-that-is-being-presented-at-the-2024-european-lung-cancer-congress

Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at ba...

 why-science-applications-international-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company r...

 why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION